Data on the interaction between prothymosin α and TLR4 may help to the design of new antiviral compounds

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 4, 2011, Pages

  Cordero, Oscar J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AUTOANTIBODY; INTERFERON; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN MD 2; PROTHYMOSIN ALPHA; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR 4;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; LETTER; MALIGNANT NEOPLASTIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION;

ANTI-HIV AGENTS; HUMANS; INTERFERON-GAMMA; PROTEIN BINDING; PROTEIN PRECURSORS; SIGNAL TRANSDUCTION; THYMOSIN; TOLL-LIKE RECEPTOR 4;

EID: 79952430850     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820a4aa7     Document Type: Letter

References (31)

1. Mosoian A, Teixeira A, High AA, et al. Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. J Virol. 2006;80:9200-9206. (Pubitemid 44359992)
2. Mosoian A, Teixeira A, Burns CS, et al. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci USA. 2010;107: 10178-10183.
3. Ueda H, Matsunaga H, Uchida H, et al. Prothymosin alpha as robustness molecule against ischemic stress to brain and retina. Ann N Y Acad Sci. 2010;1194:20-26.
4. Ueda H, Fujita R, Yoshida A, et al. Identifi- cation of prothymosin-alpha1, the necrosis-apoptosis switch molecule in cortical neuronal cultures. J Cell Biol. 2007;176:853-862. (Pubitemid 46425545)
5. Cordero OJ, Nogueira M. Thymic hormones and peptides. In: Delves PJ, Roitt IM, eds. Encyclopedia of Immunology. 2nd ed. London, United Kingdom: Academic Press; 1998: 2300-2304.
6. Cordero OJ, Maurer HM, Nogueira M. Novel approaches to immunotherapy using thymic peptides. Immunol Today. 1997;18: 10-13. (Pubitemid 27072426)
7. Letsas KP, Frangou-Lazaridis M. Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 2006;53:92-96.
8. Gòmez-Márquez J. Function of prothymosin alpha in chromatin decondensation and expression of thymosin beta-4 linked to angiogenesis and synaptic plasticity. Ann N Y Acad Sci. 2007;1112:201-209. (Pubitemid 47598659)
9. Piñeiro A, Cordero OJ, Nogueira M. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides. 2000;21: 1433-1446.
10. Hannappel E, Huff T. The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam Horm. 2003;66:257-296. (Pubitemid 137640819)
11. Butler GS, Overall CM. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov. 2009;8:935-948.
12. Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003;299: 223-226. (Pubitemid 36125203)
13. Matsunaga H, Ueda H. Stress-induced nonvesicular release of prothymosin-a initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ. 2010; 17:1760-1772.
14. Skopeliti M, Kratzer U, Altenberend F, et al. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation. Proteomics. 2007;7:1814-1824. (Pubitemid 46911001)
15. Garbin F, Eckert K, Immenschuh P, et al. Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. Int J Immunopharmacol. 1997;19: 323-332. (Pubitemid 28025428)
16. Skopeliti M, Voutsas IF, Klimentzou P, et al. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Cancer Immunol Immunother. 2006;55:1247-1257. (Pubitemid 43992051)
17. Cordero OJ, Sarandeses C, Nogueira M. Prothymosin alpha receptors on peripheral blood mononuclear cells. FEBS Lett. 1994; 341:23-27. (Pubitemid 24089183)
18. Cordero OJ, Sarandeses C, Nogueira M. Prothymosin alpha receptors on lymphocytes. J Interferon Cytokine Res. 1995;15:731-737.
19. Cordero OJ, Sarandeses C, Nogueira M. Binding of 125I-prothymosin alpha to lymphoblasts through the non-thymosin alpha 1 sequence. Life Sci. 1996;58:1757-1770.
20. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458:1191-1195.
21. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity. 2008;29:182-191.
22. Piñeiro A, Bugía MB, Arias MP, et al. Identification of receptors for prothymosin alpha on human lymphocytes. Biol Chem. 2001;382:1473-1482.
23. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326-338. (Pubitemid 47598643)
24. Hammond T, Lee S, Watson MW, et al. Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus. Cell Immunol. 2010;264:150-155.
25. Saikh KU, Lee JS, Kissner TL, et al. Toll-like receptor and cytokine expression patterns of CD56+ T cells are similar to natural killer cells in response to infection with Venezuelan equine encephalitis virus replicons. J Infect Dis. 2003;188:1562-1570. (Pubitemid 37523943)
26. Visintin A, Iliev DB, Monks BG, et al. MD-2. Immunobiology. 2006;211:437-447.
27. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24-32. (Pubitemid 46498752)
28. Skopeliti M, Iconomidou VA, Derhovanessian E, et al. Prothymosin alpha immunoactive carboxyl- terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol Immunol. 2009;46:784-792.
29. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol. 2010;87:989-999.
30. McGettrick AF, O'Neill LA. Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr Opin Immunol. 2010; 22:20-27.
31. Vlachoyiannopoulos PG, Frillingos S, Tzioufas AG, et al. Circulating antibodies to prothymosin alpha in systemic lupus erythematosus. Clin Immunol Immunopathol. 1989;53:151-160. (Pubitemid 19276579)